This session will review the Canadian Cardiovascular Society Position Statement recommendations for the management of ventricular tachycardia and ventricular fibrillation in patients with structural heart disease.
At the conclusion of this session, participants will be able to:
understand the importance of a comprehensive initial investigation for patients with VT/VF and which diagnostic tests are appropriate;
initiate appropriate acute therapy for VT/VF;
understand the indications for initiating chronic suppressive therapy for VT/VF in structural heart disease;
understand the pharmacologic, intervention and device management of patients with VT/VF in structural heart disease;
recognize alternative therapies for patients with refractory VT/VF; and